Organogenesis
Organogenesis' revenue rose 17.0% to $564 million in fiscal 2025. Its operating margin was 7.9%, up from −0.3% a year earlier. Free cash flow was −$24 million, against $4 million a year earlier. The diluted share count fell 1.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
From fiscal 2020 to 2025, earnings per share grew 0.0% a year and net income 16.6% a year, as new shares raised the share count by 17% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 114 | 102 | 104 | 136 | 94 |
| Debt incl. finance leases | 74 | 71 | 70 | — | — |
| Net debt (negative means net cash) | −40 | −31 | −34 | — | — |
| Net debt to EBITDA | −0.5x | −1.1x | −1.5x | — | — |
| Debt to equity | 0.3x | 0.3x | 0.2x | — | — |
| Interest coverage | 10.0x | 11.1x | 5.7x | −0.8x | 19.6x |
| Current ratio | 2.7x | 3.0x | 2.8x | 3.7x | 3.6x |
| Quick ratio | 2.4x | 2.6x | 2.4x | 3.4x | 3.3x |
Cash flow
Projections
Project Organogenesis' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $40,100 of Organogenesis shares on the open market, and 1 insider sold $2.6 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Mar 9, 2026 | Michael Joseph DriscollDirector | Bought | 10,000 | $2.67 | $26,700 | Form 4 |
| Mar 9, 2026 | Arthur S LeibowitzDirector | Bought | 5,000 | $2.68 | $13,400 | Form 4 |
| Dec 16, 2025 | Glenn H NussdorfDirector | Sold | 200,000 | $5.14 | $1.0 million | Form 4 |
| Nov 26, 2025 | Glenn H NussdorfDirector, 10% owner | Sold | 187,957 | $5.29 | $994,293 | Form 4 |
| Nov 25, 2025 | Glenn H NussdorfDirector, 10% owner | Sold | 12,043 | $5.30 | $63,828 | Form 4 |
| Nov 24, 2025 | Glenn H NussdorfDirector, 10% owner | Sold | 100,000 | $5.34 | $534,000 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | — | — |
| Rule of 40 | −2.4% | 12.2% | 12.7% |
| Altman Z'' | 3.57 | 4.92 | 5.27 |
| Accruals ratio | −5.7% | −2.8% | 8.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | Pass | — | — |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Pass | Pass |
| Gross margin rose | Fail | Pass | — |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 4 of 9 | — | — |
Compare
Put Organogenesis side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Organogenesis | FY25 | 17.0% | 7.9% | −4.3% | — | — | — | |
| Neogen | FY26 | −2.7% | −2.5% | 3.7% | −0.6% | 6.4x | 5 | Compare |
| Haemonetics | FY26 | −2.0% | 11.8% | 19.5% | 6.7% | 3.7x | 7 | Compare |
| Merit Medical Systems | FY25 | 11.8% | 12.2% | 14.2% | 7.7% | 0.9x | 8 | Compare |
| Lantheus | FY25 | 0.5% | 20.2% | 23.0% | 22.7% | 0.6x | 5 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 139 | 198 | 193 | 261 | 338 | 467 | 451 | 433 | 482 | 564 |
| Revenue growth | — | 43.1% | −2.5% | 34.9% | 29.6% | 38.1% | −3.5% | −3.9% | 11.3% | 17.0% |
| Gross profit | 90 | 137 | 125 | 185 | 251 | 353 | 346 | 327 | 366 | — |
| Research and development | 6 | 9 | 11 | 15 | 20 | 31 | 40 | 44 | 50 | 44 |
| Operating income | −9 | −6 | −52 | −30 | 27 | 72 | 22 | 12 | −1 | 45 |
| Net income | −17 | −8 | −65 | −39 | 17 | 94 | 16 | 5 | 1 | 37 |
| Diluted EPS (US$) | −0.27 | −0.14 | −0.94 | −0.42 | 0.15 | 0.70 | 0.12 | 0.04 | −0.01 | 0.15 |
| Diluted shares (millions) | 63 | 64 | 69 | 93 | 111 | 134 | 132 | 133 | 132 | 130 |
| Cash flow | ||||||||||
| Cash from operations | −5 | −4 | −61 | −34 | 6 | 62 | 25 | 31 | 14 | −10 |
| Capital expenditure | 1 | 2 | 2 | 6 | 18 | 31 | 34 | 24 | 10 | 14 |
| Free cash flow | −6 | −6 | −62 | −40 | −12 | 31 | −9 | 7 | 4 | −24 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26 | 0 |
| Acquisitions | 0 | 12 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 1 | 1 | 1 | 2 | 4 | 7 | 9 | 11 | 13 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 2 | 2 | 21 | 60 | 84 | 114 | 102 | 104 | 136 | 94 |
| Debt incl. finance leases | — | 52 | 15 | 50 | 85 | 74 | 71 | 70 | — | — |
| Total assets | 311 | 149 | 164 | 221 | 290 | 443 | 449 | 460 | 498 | 599 |
| Total liabilities | 11 | 157 | 117 | 165 | 148 | 202 | 184 | 181 | 113 | 165 |
| Shareholders' equity | −16 | −15 | 40 | 52 | 142 | 241 | 266 | 279 | 263 | 300 |
| Margins and ratios | ||||||||||
| Gross margin | 65.3% | 69.2% | 64.4% | 70.9% | 74.2% | 75.6% | 76.7% | 75.4% | 76.0% | — |
| Operating margin | −6.3% | −2.8% | −26.6% | −11.4% | 7.9% | 15.4% | 5.0% | 2.9% | −0.3% | 7.9% |
| Net margin | −12.2% | −4.2% | −33.5% | −14.8% | 5.1% | 20.2% | 3.4% | 1.1% | 0.2% | 6.6% |
| Free cash flow margin | −4.5% | −3.0% | −32.3% | −15.1% | −3.6% | 6.6% | −2.0% | 1.5% | 0.9% | −4.3% |
| Rule of 40 (growth + FCF margin) | — | 40.1% | −34.9% | 19.8% | 26.0% | 44.7% | −5.5% | −2.4% | 12.2% | 12.7% |
| Return on capital | — | — | −108.3% | −55.1% | 27.7% | 42.0% | 7.8% | 2.6% | — | — |
| Return on equity | — | — | −526.6% | −84.2% | 17.8% | 49.2% | 6.1% | 1.8% | 0.3% | 13.2% |
| Return on assets | — | −3.6% | −41.5% | −20.1% | 6.8% | 25.7% | 3.5% | 1.1% | 0.2% | 6.8% |
| Net debt to EBITDA | — | 371.5x | — | — | 0.0x | −0.5x | −1.1x | −1.5x | — | — |